A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients

INTRODUCTION: Sorafenib has demonstrated single agent activity in non-small cell (NSCLC) and small cell lung cancer (SCLC). Carboplatin/pemetrexed (CbP) and cisplatin/etoposide (PE) are commonly used in the treatment of these diseases. METHODS: A phase I trial escalating doses of sorafenib in combin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Davies, Janine M., Dhruva, Nirav S., Walko, Christine M., Socinski, Mark A., Bernard, Stephen, Hayes, D. Neil, Kim, William Y., Ivanova, Anastasia, Keller, Kimberly, Hilbun, Layla R., Chiu, Michael, Dees, E. Claire, Stinchcombe, Thomas E.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978774/
https://ncbi.nlm.nih.gov/pubmed/20580118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2010.05.022
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items